Boehringer Ingelheim to join Structural Genomics Consortium

New partnership could pave the way for previously undiscovered cures

Boehringer Ingelheim has today (May 8th) announced that it will join with the Structural Genomics Consortium (SGC) in a partnership that will focus its attention on research into incurable diseases.

Dr Adrian Carter, corporate-vice president of Global Research Networking of Boehringer Ingelheim said the company is "excited" about the agreement, which will see the two organisations investigate protein structures and epigenetics.

This could in turn uncover information that could pave the way for novel therapies for previously incurable diseases.

The SGC and Boehringer Ingelheim will carry out a number of projects together, the most notable of which involve the study of activity of proteins involved in epigenetic control.

"This is a unique opportunity to work on unprecedented science in a precompetitive public-private partnership with a large global scientific network," Mr Carter said, of the partnership.

"We hope that it will help us in starting new drug discovery programs in areas of high unmet medical need."